Gao Lei, Wu Guo-jun, Liu Bei, Shen Ming-zhi, Pan Tie-jun, Yu Chui-gong, Wang Qin-hao, Ru Yi, Liu Xi-ping, Niu Tian-shui, Wang Guo-dong, Wei Ming, Li Rui-xiao, Yao Libo, Wang He, Li Xia
Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China ; Department of Urology, Tangdu Hospital, the Fourth Military Medical University, Xi'an, China ; Department of Urology, Wuhan General Hospital, Guangzhou Command PLA, Wuhan, China.
Department of Urology, Xijing Hospital, the Fourth Military Medical University, Xi'an, China.
PLoS One. 2013 Dec 20;8(12):e84127. doi: 10.1371/journal.pone.0084127. eCollection 2013.
The majority of renal cell carcinomas (RCCs) are characterized by loss of function of the tumor suppressor gene von Hippel Lindau (VHL), which acts as ubiquitin ligase for hypoxia-inducible factor-1α (HIF-1α). In the absence of VHL, HIF-1α protein becomes stabilized and contributes to tumorigenesis. Recent data demonstrate the antitumor efficacy of VHL promoter in RCC cells. This study demonstrates that N-Myc downstream-regulated gene 2 (NDRG2) is a potential regulator of VHL. NDRG2 is involved in proliferation and invasion of cancer cell, furthermore it is frequently down-regulated in renal cell carcinoma. Herein we evaluated the effect of NDRG2 overexpression on proliferation and invasion in human renal cancer cells. The human renal cancer cell line 786-O and A498 were infected with Ad-NDRG2 or Ad-LacZ. Overexpression of NDRG2 not only inhibited the growth of the cells, but also suppressed the invasion. Further study showed that the tumor suppressor gene VHL were up-regulated, whereas transcription factor HIF-1a and vascular endothelial growth factor (VEGF) were down-regulated in 786-O cells infected by Ad-NDRG2. Finally, in a nude mouse model, intratumoral injections of Ad-NDRG2 every 3 days for a total of seven times significantly inhibited the growth and angiogenesis of xenografted 786-O tumors. In conclusion, these data indicate that NDRG2 may be involved in proliferation and invasion by impacting the expression of VHL and HIF-1α. NDRG2 may be an attractive therapeutic target for renal cell carcinoma.
大多数肾细胞癌(RCC)的特征是抑癌基因冯·希佩尔-林道(VHL)功能丧失,VHL作为缺氧诱导因子-1α(HIF-1α)的泛素连接酶。在没有VHL的情况下,HIF-1α蛋白变得稳定并促进肿瘤发生。最近的数据表明VHL启动子在RCC细胞中具有抗肿瘤功效。本研究表明N-Myc下游调节基因2(NDRG2)是VHL的潜在调节因子。NDRG2参与癌细胞的增殖和侵袭,此外它在肾细胞癌中经常下调。在此我们评估了NDRG2过表达对人肾癌细胞增殖和侵袭的影响。人肾癌细胞系786-O和A498用Ad-NDRG2或Ad-LacZ感染。NDRG2的过表达不仅抑制了细胞的生长,还抑制了侵袭。进一步研究表明,在Ad-NDRG2感染的786-O细胞中,抑癌基因VHL上调,而转录因子HIF-1α和血管内皮生长因子(VEGF)下调。最后,在裸鼠模型中,每3天瘤内注射Ad-NDRG2,共7次,显著抑制了异种移植的786-O肿瘤的生长和血管生成。总之,这些数据表明NDRG2可能通过影响VHL和HIF-1α的表达参与增殖和侵袭。NDRG2可能是肾细胞癌有吸引力的治疗靶点。